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Background In a randomized, controlled trial (RCT) on childhood eczema we
reported that substituting nurse practitioners (NPs) for dermatologists resulted in
similar outcomes of eczema severity and in the quality of life, and higher patient
satisfaction.
Objectives To determine costs and cost-effectiveness of care provided by NPs vs.
dermatologists and to compare our results with those in studies from other coun-
tries.
Methods We estimated the healthcare costs, family costs and the costs in other
sectors alongside the RCT. All the costs were linked to quality of life [Infants’
Dermatitis Quality of Life Index (IDQOL), Children’s Dermatology Life Quality
Index (CDLQI)] and to patient satisfaction (Client Satisfaction Questionnaire-8)
to determine the incremental cost-effectiveness ratio (ICER). We also examined
all the reported studies on the costs of childhood eczema.
Results The mean annual healthcare costs, family costs and costs in other sectors
were €658, €302 and €21, respectively, in the NP group and €801, €608 and
€0Æ93, respectively, in the dermatologist group. The ICER in the NP group com-
pared with the dermatologist group indicated €925 and €751 savings per one
point less improvement in IDQOL and CDLQI, respectively, and €251 savings per
one point more satisfaction in the NP group at 12 months. The mean annual
healthcare costs and family costs varied considerably in the six identified studies.
Conclusions Substituting NPs for dermatologists is both cost-saving and cost-effec-
tive. The treatment of choice is that provided by the NPs as it is similarly effec-
tive to treatment provided by a dermatologist with a higher parent satisfaction.
International comparisons are difficult because the types of costs determined, the
units and unit prices, and eczema severity all differ between studies.
Educational interventions and coaching focusing on both
somatic and psychological aspects have been used as an
adjunct to conventional care for children with eczema to
enhance the effectiveness of therapy.1–3 The effectiveness of
providing nursing intervention as an addition to conventional
care by a dermatologist in children with eczema was evaluated
in several studies.4–6 Our approach is different because in our
recently published randomized, controlled trial (RCT) the edu-
cation and coaching by the nurse practitioner (NP) was not
supplementary, but was a part of the overall treatment (i.e.
also medical treatment) by the NP.7 The effectiveness of
substituting NPs for dermatologists to provide care for
children with eczema was comparable in terms of severity and
quality-of-life outcomes. In addition, parents whose children
were treated by the NP were significantly more satisfied.
Treatment of eczema in children is accompanied by signifi-
cant costs, which are covered by health insurance, the families
and society. There is a need for economic evaluations of
nurse-led care in the treatment of eczema in children; unfor-
tunately the lack of rigorously designed trials provides only
poor quality efforts in this area.8 Substituting NPs for derma-
tologists may decrease healthcare costs. However, although
using NPs may save salary costs, they may order more labora-
tory tests, issue more prescriptions and conduct more visits
thus reducing the overall cost savings. We undertook an eco-
nomic evaluation comparing NP-provided care of eczema in
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children with that provided by dermatologists, alongside an
RCT in which costs were measured from a societal perspec-
tive, and we present the results of a cost-effectiveness analysis.
In addition, we examined the currently reported international
costs of eczema in children for an accurate comparison with
those in the present study.
Methods
Study population
In a randomized, parallel-group study, 160 new referrals aged
£ 16 years with a diagnosis of eczema (‘atopic dermatitis’)9
were randomized to either conventional care by a dermato-
logist or to care by a NP. The duration of the study was
1 year. The design, the inclusion criteria and the sample size
of the RCT have been published previously.7
Clinical effectiveness parameters
The primary endpoints were between-group (dermatologist
and NP) differences in the quality of life of the child between
baseline and the follow-up at 12 months assessed by the
Infants’ Dermatitis Quality of Life Index (IDQOL)10 completed
by parents for children aged < 4 years, and by the illustrated
version of the Children’s Dermatology Life Quality Index
(CDLQI)11 completed by the children aged 4–16 years. The
IDQOL and CDLQI instruments each have 10 items which are
added up to provide a score that ranges from 0 to 30, with
the higher scores representing a poor quality of life.
Patient satisfaction was measured by the Client Satisfaction
Questionnaire-8 (CSQ-8)12 at 12 months. Responses to the
eight items on the CSQ-8 were scored on a scale from 1
(unfavourable expression) to 4 (most positive expression).
The aggregated sum score has a maximum of 32, with a
higher score representing more satisfaction. The CSQ-8 was
completed by the parents at home and returned to the inde-
pendent data entry office.
Costs
Resource data were collected prospectively during study visits
with an independent investigator at 4, 8 and 12 months. A
detailed registration system was set up and incorporated into
the clinical record form. Visits to dermatologists and NPs,
phone consultations, group education sessions, admission days
and laboratory tests were registered every study visit by the
investigator by comparing the medical record and the elec-
tronic hospital information system, and was completed
together with the patient. Absence from work for visits to the
dermatologist or NP, travelling expenses, out-of-pocket
expenses, professional help at home and visits to the general
practitioner were registered in a cost diary. The parents com-
pleted the diary at home and handed it over to the investigator
during the next study visit. Volumes of medication used
and refilled prescriptions were measured using registration
forms and compared with the medical record during every
study visit. This was compared with prescription records
obtained from the pharmacy database. Measurement of costs
covered eczema-specific costs and resource utilization.
Eczema-related costs, for example costs for visits to the aller-
gologist or dietician, are not included in the calculation. The
three categories of costs were the healthcare costs (hospital
costs and community costs), the family costs and the costs in
other sectors, aggregated to estimate the mean annual societal
costs.13 Hospital costs were recorded from the start of
the study until the last outpatient visit to the dermatologist or
the NP. Community costs were recorded after treatment in
hospital was completed until the end of the 1-year study period.
Unit prices and cost calculations
Estimates of unit costs were based on the Dutch guideline
prices.14 Group education sessions of 2 h were calculated and
divided by the number of participants to determine the allo-
cated amount per patient. Costs of laboratory tests were based
on charges.14 Costs of medications were based on the listed
prices, including value added tax, obtained from the website
of the Dutch Health Insurance Board (http://www.fk.cvz.nl).
Travel costs by private car or public transport were based on
the distance travelled to the hospital. Travelling expenses were
calculated per visit. The mean distance to hospital was
11Æ7 km (23Æ4 km per visit), and cost per km amounted to
€0Æ17. In addition, parking costs were estimated at €2Æ64 per
visit when a private car was used for transportation. Costs due
to productivity losses were based on an overall mean hour
productivity cost for men and women, calculated according to
the human capital approach.14 Costs of productivity losses
by the parents only include losses due to visits to healthcare
providers.
Multiplying the respective volumes of resource use with
their corresponding unit prices resulted in the associated total
costs. Costs were calculated in the European currency (Euro).
The price level is that of 2008. A detailed outline of the cost
categories, determinations, units and unit prices that were
assessed is presented in Table 1.
Statistical analysis
For the objective SCORAD (SCORing AD), quality-of-life out-
comes and patient satisfaction, the paired t-test was used for
post-hoc comparisons within the treatment groups and the
unpaired t-test for comparisons between the treatment groups.
In case scores were not normally distributed, the Friedman test
was used for comparisons within groups, and the Mann–
Whitney U-test for between-group comparisons.
Descriptive analyses were used to describe the mean costs
per patient in both treatment groups. Differences in costs
between the intervention group and the control group after
12 months of the study were presented based on the trial
data, and 95% confidence intervals (CIs) were computed based
on bootstrap resampling with 5000 replications of the trial
 2011 The Authors
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data. Separate estimates were made for different cost catego-
ries. The costs of care by the dermatologist and the NP were
estimated for different eczema severity rates.
For the cost-effectiveness analyses, mean annual societal
costs were linked to quality of life (IDQOL and CDLQI) and
to patient satisfaction (CSQ-8). Point estimates for the incre-
mental cost-effectiveness ratio (ICER) were computed on com-
plete cost-effect pairs by dividing the incremental societal
costs by the incremental effects at 12 months. We estimated
uncertainty around the ICERs using bootstrapping, generating
5000 replications of the original dataset. The percentage of
patients who fell into each of the four quadrants of the cost-
effectiveness plane was determined. A cost-effectiveness
acceptability curve (CEAC) was generated representing the
probability that care by the NP was more effective compared
with care by the dermatologist over a range of thresholds.13,15
Finally, a sensitivity analysis was performed to examine the
robustness of our findings. We investigated the scenario when
60% of the children in the NP group participated in a 1-h
group education session with five children per group. We
have assumed an average decrease of 0Æ5 visits per child in the
NP group. This scenario was based on expert opinions of the
professionals at our department.
Literature review
A literature search was conducted in October 2009 for an
overview of the cost-of-illness (COI) of eczema in children
worldwide. Medline, EMBASE, the Cochrane library database
and the CINAHL databases were searched. There was no
restriction on language or country of origin. Search terms
were atopic dermatitis, atopic eczema, eczema, costs, cost
analysis, economics, child, infant and adolescent. Studies in
which the cost of eczema in children and adults was com-
bined were excluded if we were unable to extract data that
related to children. MeSH terms and text word combinations
were used. We also hand searched the reference lists of all
identified studies for additional studies.
The selected papers were independently appraised in terms
of their methodological quality by using the Consensus on
Health Economic Criteria (CHEC)-list16 and data were
extracted by three reviewers (M.L.A.S., K.M.V., P.J.C.). Differ-
ences of opinion were resolved by consensus. Because there is
no generally accepted list of criteria for reviewing economic
evaluations based on COI studies, we used the CHEC-list,
which was developed for reviews of full economic evaluations
based on effectiveness studies. The CHEC-list consists of 19
yes-or-no questions. In the evaluation of the COI studies some
items on effectiveness could not be assessed and were scored
as not applicable. As a generic measure adjusted for ‘not appli-
cable’ we determined the percentage of ‘yes’ answers from
the total answered questions. The data extraction took place
by means of a data extraction form that was set up by the
authors.
COI estimates for each country were converted into Euro
(€) using an exchange rates website (http://www.x-rates.
com). We choose 31 December as the standard for the year of
the original study. The cost estimates for each country were
adjusted for inflation beginning with the year of data sam-
pling of the original paper and then indexed to the price level
Table 1 Types of costs, determinations, unit and unit prices
Types of costs Determination Unit Unit price (€)
Healthcare costs hospital
Visits dermatologista Number of visits, salary costs calculated to invested time Min 1Æ66
Visits NPb Number of visits, salary costs calculated to invested time Min 0Æ52
Phone consultations
dermatologistc
Number of visits, salary costs calculated to invested time Min 8Æ30
Phone consultations NPd Number of visits, salary costs calculated to invested time Min 5Æ20
Prescriptions Quantities of medication and unit prices Prescription Diverse
Laboratory tests Number of tests Diverse
Admission day The number of bed days, standard price Day 512
Group education session
by the NP
Specific salary costs calculated to invested time divided by
the number of participants
Diverse
Healthcare costs community
Visits GP Number of visits, standard price Visit 21Æ70
Prescriptions Quantities of medication and unit prices Variable
Family costs
Absence from work Time investment, mean income Dutch population costs Hour 37Æ23
Travelling expenses Standard price for private car ⁄public transport based on
mean distance to hospital
Visit 6Æ72 ⁄4Æ04
Out-of-pocket Resources used Variable
Costs in other sectors
Home help visits Number of visits, invested time Hour 32Æ97
NP, nurse practitioner; GP, general practitioner. aFirst visit 20 min, follow-up visits 10 min; bfirst visit NP 30 min, follow-up visits 20 min;
cphone consultations 5 min; dphone consultations NP 10 min.
 2011 The Authors
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of 2008 using the consumer price index on the website of
Centraal Bureau voor de Statistiek (CBS), the Netherlands
(http://cbs.nl).
Results
In this RCT, 79 patients were allocated to the dermatologist
group and 81 to the NP group. The severity of the eczema
measured by the mean objective SCORAD17 (SD) did not dif-
fer significantly between the treatment groups at baseline [in
children aged < 4 years: dermatologist group 33Æ4 (19Æ3), NP
group 33Æ4 (15Æ6); and in children aged 4–16 years: derma-
tologist 35Æ4 (17Æ3), NP 29Æ9 (16Æ0)]. The difference of only
5Æ5 points between the dermatologist and NP groups in the
age group 4–16 years cannot be assumed to be clinically rele-
vant as the range of the objective SCORAD is from 0 to 83.
More details on the baseline characteristics have been reported
elsewhere.7
Clinical effectiveness
In children aged < 4 years, the mean number of outpatient
visits per patient was 4Æ5 in the dermatologist group and 3Æ5
in the NP group (P = 0Æ043). In children aged 4–16 years,
there was no significant difference between the dermatolo-
gists (3Æ6) and the NPs (3Æ7). The mean number of tele-
phone consultations per patient was significantly higher in
the NP group both in children aged < 4 years (P < 0Æ001)
and in children aged 4–16 years (P = 0Æ003). The mean
time investment (outpatient visits, phone consultations) per
patient per year was 52 min in the dermatologist group and
100 min in the NP group. In the NP group, on average, five
parents in each age group participated in one group educa-
tion session of 2 h. The mean hospital period was
9Æ3 months in the dermatologist group and 7Æ4 months in
the NP group.
The mean IDQOL score in the dermatologist group
improved significantly from 11Æ6 (SD 8Æ1; 95% CI 9Æ0–14Æ2)
at baseline to 5Æ6 (SD 3Æ9; 95% CI 4Æ3–7Æ0) at 12 months with
a mean change from baseline of )6Æ5 (SD 6Æ6; 95% CI )14Æ2
to )8Æ9; P < 0Æ001). The mean IDQOL score in the NP group
improved significantly from 10Æ7 (SD 4Æ9; 95% CI 9Æ1–12Æ3)
at baseline to 5Æ7 (SD 5Æ4; 95% CI 4Æ0–7Æ5) at 12 months with
a mean change from baseline of )4Æ9 (SD 5Æ5; 95% CI )6Æ8
to )3Æ0; P < 0Æ001). The between-groups difference was
())1Æ7 (95% CI )4Æ6 to 1Æ2; P = 0Æ26).
The mean CDLQI score in the dermatologist group
improved significantly from 12Æ1 (SD 6Æ3; 95% CI 9Æ9–14Æ2)
at baseline to 5Æ6 (SD 4Æ2; 95% CI 4Æ2–7Æ1) at 12 months with
a mean change from baseline of )5Æ9 (SD 6Æ0; 95% CI )8Æ0
to )3Æ9; P < 0Æ001). The mean CDLQI score in the NP group
improved significantly from 10Æ0 (SD 4Æ4; 95% CI 8Æ5–11Æ4)
at baseline to 4Æ9 (SD 3Æ5; 95% CI 3Æ7–6Æ1) at 12 months with
a mean change from baseline of )5Æ2 (SD 4Æ0; 95% CI )6Æ6
to )3Æ8; P < 0Æ001). The between-groups difference was
())0Æ7 (95% CI )3Æ3 to 1Æ7; P = 0Æ55).
The CSQ-8 scores were 24Æ8 (SD 4Æ3; 95% CI 23Æ6–26Æ0) in
the dermatologist group and 26Æ9 (SD 4Æ9; 95% CI 25Æ5–28Æ2)
in the NP group at the 12-month follow-up. The between-
groups comparisons showed a significant difference at
12 months of ())2Æ1 (95% CI )3Æ0 to )0Æ3; P < 0Æ02) in
favour of the NP group.
Costs
In the present study, data were analysed for children for whom
cost data were available: 76 in the dermatologist group and 71
in the NP group. The mean resource use for the dermatologist
and NP groups is described in Table 2. The mean annual socie-
tal costs per patient were €1409 in the dermatologist group
and €981 in the NP group (mean difference )€428; 95% CI
)910 to 197). In the dermatologist group these costs were
€1791 in children aged < 4 years and €1039 in children aged
4–16 years. In the NP group these costs were €1186 in chil-
dren aged < 4 years and €778 in children aged 4–16 years.
The mean costs for each resource item are described in
Table 3. The costs of dermatologist care and NP care estimated
for different eczema severity levels are shown in Table 4.
Healthcare costs
Mean annual healthcare costs were higher in the dermatologist
group (€801) than in the NP group (€658) (mean difference
)€143; 95% CI )544 to 299). In the hospital period, these
costs were €771 in the dermatologist group and €632 in the
NP group. In the dermatologist group, higher costs were
noted for outpatient visits, laboratory tests and medication.
Costs for phone consultations and protective dressings were
Table 2 Mean (SD) total costs (€) and cost
difference per child during the 1-year study




(n = 71) Differencea (95% CI)
Healthcare costs hospital 632 (1198) 771 (1590) )139 ()520 to 291)
Healthcare costs community 26 (39) 30 (59) )4 ()17 to 12)
Family costs 302 (511) 608 (1018) )306 ()475 to )16)
Costs other sectors 21 (182) 0Æ93 (7Æ83) 20 ()3 to 59)
Total costs 981 (1339) 1409 (2289) )428 ()910 to 197)
CI, confidence interval. aNegative cost differences represent lower costs in the nurse practi-
tioner arm.
 2011 The Authors
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slightly higher in the NP group. In the community period, the
costs for visits to the general practitioner were €18 in the der-
matologist group and €10 in the NP group.
Family costs
Mean annual family costs were twice as high in the dermatol-
ogist group (€608) than in the NP group (€302) (mean dif-
ference )€306; 95% CI )475 to )16). Time costs because of
visits to healthcare providers were €415 in the dermatologist
group and €178 in the NP group. Costs for out-of-pocket
expenses were €134 in the dermatologist group and €83 in
the NP group.
Costs in other sectors
Mean annual costs for home help visits, which are paid by the
state in the Netherlands, were €21 in the NP group and €0Æ93
in the dermatologist group.
Cost-effectiveness analyses
The results of the cost-effectiveness analyses are shown in
Figure 1. The point estimate for the ICER was €925 indicating
that one point less improvement in IDQOL in the NP group
compared with the dermatologist group at 12 months would
save €925. However, the effectiveness of the two interventions
was comparable with a clear difference in costs in favour of
the NP group. Therefore an ICER provides little additional
information. For that reason we performed bootstrapping,
which showed a 95% CI of )€5748 to €6667. The cost-effec-
tiveness plane showed that 51% of the cost-effect pairs were
plotted in the southwest quadrant, indicating lower costs and
less effect in the NP group. Twenty-nine per cent of the
resamples were located in the southeast quadrant indicating
lower costs and more effect in the NP group. The CEAC
showed that without additional investment the probability that
the NP is cost-effective is 80%, which decreases quickly by
investment because the benefit can only be explained by lower
costs and not by gained quality of life.
For the CDLQI, the ICER was €751 per one point less
improvement in CDLQI in the NP group. Bootstrapping
showed a CI of )€3653 to €3213. The cost-effectiveness plane
showed that 59% of the cost-effect pairs were plotted in the
southwest quadrant, indicating lower costs and less effect in
the NP group. Thirty-seven per cent of the cost-effect pairs
were located in the southeast quadrant, which indicates lower
costs as well as more effect in the NP group. The CEAC
Table 3 Mean (SD) costs (€) and cost
difference per child per resource item during










Outpatient visits 272 (143) 422 (238) )150 ()194 to )75)
Phone consultations 7Æ22 (9Æ23) 3Æ63 (7Æ72) 3Æ59 (0Æ91 to 5Æ93)
Oral medication 14 (36) 19 (30) )5 ()14 to 6)
Ointments active ingredients 69 (80) 87 (113) )18 ()42 to 15)
Emollients 17 (19) 17 (22) 0 ()6Æ48 to 5Æ92)
Bandages, dressings 47 (69) 26 (60) 21 (2 to 40)
Laboratory tests 9 (33) 17 (40) )8 ()17 to 4)
Hospital admission days 179 (1133) 163 (1376) 16 ()334 to 380)
Group education, NP 4Æ63 (7Æ91) – 4Æ63 (2Æ65 to 5Æ89)
Healthcare cost community
General practitioner 10 (28) 18 (36) )8 ()15 to 3)
Oral medicationb 3Æ06 (13Æ42) 2Æ81 (10Æ30) 0Æ25 ()2Æ97 to 4Æ05)
Ointments with active
ingredientsc
6Æ54 (21Æ09) 7Æ14 (40Æ20) )0Æ86 ()10Æ43 to 7Æ62)
Emollients 3Æ20 (5Æ79) 1Æ45 (3Æ93) 1Æ75 (0Æ28 to 3Æ08)
Protective dressingsd 2Æ64 (11Æ07) 0 (0) 2Æ64 (0Æ48 to 4Æ88)
Total healthcare costs 658 (1213) 801 (1607) )143 ()544 to 299)
Family costs
Time costse 178 (357) 415 (735) )237 ()360 to )37)
Travelling expenses 20 (18) 30 (26) )10 ()13 to )1)
Bath oil 21 (20) 23 (26) )2 ()8 to 6)
Out-of-pocketf 83 (370) 134 (684) )51 ()221 to 97)
Costs other sectors
Home-help visits 21 (182) 0Æ93 (7Æ83) 20 ()3 to 59)
aNegative cost differences represent lower costs in the NP arm; bantibiotics, antihistamines;
csteroids, calcineurin inhibitors, tar; dbandages, garments and gloves; etime missed in paid
work and days missed in nonworking activities of the parents; fself-medication, alternative
practitioner, carpet changes, nutrition.
 2011 The Authors
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showed that without additional investment the probability that
the NP is cost-effective is 96%, but this decreases quickly by
investment because the benefit can only be explained by lower
costs in the NP group and not by gained quality of life.
For the CSQ-8, ICER was €251, which means per patient
€251 lower costs per one point more satisfaction in the NP
group. Bootstrapping showed a CI of )€1555 to €146.
Ninety-two per cent of the replicates were plotted in the
southeast quadrant, which means that treatment by the NP
gave lower costs and more satisfaction. The CEAC showed that
without additional investment the probability that the NP is
cost-effective is 94% which increases to 99% by some invest-
ment.
In the sensitivity analysis, the mean annual societal costs per
patient were €944 in the NP group instead of €981. For the
CSQ-8, the ICER was €270 instead of €251 in the NP group.
Literature review
From the searches, 137 studies were identified and their
abstracts were assessed. Criteria for study selection included
availability of estimates of healthcare and ⁄or family costs of
eczema in infants or children or adolescents. Both COI studies
and cost-effectiveness studies were taken into account, as the
aim was to give an overview of the COI of eczema in children
without restricting the selection to any particular objectives.
We excluded studies in which the cost of eczema in children
and adults was combined because we were unable to extract
data that related to children. Six studies were included in this
review. The studies reported the costs of eczema in children
in Australia,18 Germany,19–21 U.K.22 and Italy.23 Five articles
concerned COI studies,18,20–23 and one study concerned cost-
effectiveness.19 An overview of the characteristics of the
studies is shown in Table 5.
The results of methodological assessment are shown in
Table 6. Three out of five COI studies18,20,22 scored ‡ 50%
positive answers. The COI study of Emerson et al.22 scored the
best with a percentage of 77% (10 out of 13).
The studies used different frameworks to evaluate costs. An
overview is shown in Table 7. Witt et al.19 compared the cost-
effectiveness of homoeopathic vs. conventional therapy for
eczema in children. To compare our study with the five COI





















Outpatient visits 178 (85) 270 (147) 340 (143) 257 (152) 404 (206) 521 (260)
Phone consultations 1Æ21 (1Æ99) 6Æ55 (8Æ13) 13 (12) 3Æ93 (9Æ49) 2Æ04 (6Æ33) 5Æ17 (8Æ05)
Oral medication 0 (0) 15 (44) 20 (26) 16 (33) 12 (21) 28 (35)
Ointments active ingredients 35 (50) 71 (88) 85 (72) 26 (24) 83 (122) 118 (118)
Emollients 18 (18) 18 (21) 13 (17) 18 (12) 16 (17) 19 (30)
Bandages, dressings 15 (29) 45 (73) 73 (70) 16 (57) 17 (49) 40 (71)
Laboratory tests 11 (34) 12 (39) 0Æ45 (2Æ0) 7Æ62 (20Æ74) 19 (33) 19 (53)
Hospital admission days 0 (0) 0 (0) 6Æ80 (2Æ71) 0 (0) 0 (0) 429 (2239)
Group education, NP 4Æ4 (9Æ52) 5Æ84 (8Æ48) 2Æ10 (4Æ61) – – –
Total 287 (141) 450 (280) 1237 (2222) 386 (149) 567 (284) 1192 (2528)
Healthcare costs community
General practitioner 11 (25) 13 (33) 3Æ3 (10Æ6) 13 (24) 11 (22) 25 (47)
Oral medicationa 0 (0) 4Æ9 (17) 0Æ9 (3Æ9) 8Æ90 (17Æ40) 1Æ69 (8Æ93) 1Æ27 (6Æ00)
Ointments with active ingredientsb 1Æ23 (3Æ4) 3Æ16 (10Æ6) 17 (36) 8Æ30 (21Æ80) 2Æ20 (6Æ68) 12 (62)
Emollients 3Æ97 (6Æ5) 3Æ50 (6Æ3) 2Æ1 (3Æ89) 2Æ75 (6Æ25) 1Æ17 (2Æ76) 1Æ18 (3Æ72)
Protective dressingsc 3Æ24 (8Æ60) 1Æ15 (7Æ74) 5Æ47 (16Æ90) 0 (0) 0 (0) 0 (0)
Total 19 (27) 26 (40) 30 (43) 35 (57) 17 (25) 42 (82)
Total healthcare costs 307 (146) 476 (275) 1267 (2254) 420 (144) 584 (295) 1234 (2553)
Family costs
Time costsd 31 (72) 153 (291) 320 (520) 315 (428) 256 (396) 645 (1048)
Travelling expenses 13 (16) 20 (17) 26 (20) 17 (13) 25 (20) 42 (32)
Bath oil 17 (63) 301 (560) 440 (516) 25 (50) 22 (17) 23 (22)
Out-of-pockete 15 (28) 110 (432) 64 (113) 33 (37) 233 (1023) 69 (201)
Total 77 (63) 301 (560) 440 (516) 366 (440) 522 (1068) 761 (1141)
Costs other sectors
Home-help visits 0 (0) 36 (239) 0 (0) 0 (0) 0 (0) 2Æ13
Total costs all categories 384 (128) 814 (707) 1707 (2256) 811 (518) 1128 (1100) 2022 (3452)
aAntibiotics, antihistamines; bsteroids, calcineurin inhibitors, tar; cbandages, garments and gloves; dtime missed in paid work and days mis-
sed in nonworking activities of the parents; eself-medication, alternative practitioner, carpet changes, nutrition.
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studies we have only included the costs of conventional ther-
apy in our comparison.
Comparison of healthcare costs
In the U.K., in 2001, Emerson et al.22 reported annual costs of
€90 in children with eczema. The severity of eczema was
largely mild (83%), the visits were mainly in primary care,
and there were no costs for hospital admission, which
explains the lower costs compared with the other studies.
In Germany, in 2000, Rathjen et al.21 reported annual costs
of €1498 in moderate to severe eczema. Hospitalization,
€384, and rehabilitation clinic, €526, were included. In
2003, Weinmann et al.20 reported eczema-specific costs in a
birth cohort in which children with atopic diseases were
included. Costs were expressed as costs per disease-year and
Fig 1. Bootstrapped costs and effects per outcome parameter (left panels) and cost-effectiveness acceptability curves displaying the probability
of the nurse practitioner (NP) being cost-effective compared with the care as usual (right panels). Substantial proportions of the joint density
(DC, DE) cover all four quadrants of the cost-effectiveness plane. For Infants’ Dermatitis Quality of Life Index (IDQOL) and Children’s
Dermatology Life Quality Index (CDLQI), the majority is contained within the southwest quadrant (less costly, less effective). For the Client
Satisfaction Questionnaire-8 (CSQ-8), the majority is contained within the southeast quadrant (more effective, less costly).
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represent the total annual eczema-specific healthcare costs of
€228 in years with symptoms. Hospitalization, €30, and
rehabilitation clinic, €70, were included. In 2009, Witt
et al.19 reported annual costs of €331 in children with mild
eczema. No costs for hospitalization and rehabilitation clinic
were included.
In Australia, in 1997, Su et al.18 estimated annual costs of
€501, €1448 and €2206 for mild, moderate and severe
eczema, respectively, at a dermatology clinic. Hospital-based
recruiting and costs for eczema-related visits to different phys-
icians explain the higher costs. A large part of the healthcare
costs consisted of hospitalization: in mild, moderate and
severe eczema, respectively, €343, €1154 and €486. Medica-
tion was not included in this estimation.
Comparison of family costs
In the U.K., Emerson et al.22 estimated annual costs of €52. In
Germany, Rathjen et al.21 estimated annual costs of €4068;
most of these costs were because of the time spent on the
treatment and the care. Witt et al.19 estimated annual costs of
€360. In Australia, Su et al.18 estimated annual costs of €364,
€1297 and €977 for mild, moderate and severe eczema,
respectively. In Italy, Ricci et al.23 estimated annual costs of
€727, €1228 and €1896 for mild, moderate and severe
eczema, respectively; most of the family costs were for emol-
lients and detergents in all three severity categories.
Discussion
Our results clearly show that substituting NPs for dermatolo-
gists in the treatment of eczema in children provides savings
in both healthcare costs and family costs. Care provided by
the NPs was at least as effective as that provided by the
dermatologists and may be preferable from a health economic
perspective.
Healthcare costs for outpatient visits were lower in NP-led
care because of the lower salary costs, and because of a lower
number of outpatient visits in children aged < 4 years. This
was somewhat offset by higher telephone costs in the NP
group because carrying out extensive counselling by phone
was accompanied by additional costs. The treatment period in
the hospital was longer in the dermatologist group. Neverthe-
less, after treatment in the hospital was completed, the costs
for visits to the general practitioner were higher in the derma-
tologist group indicating that patients treated by the NP were
autonomous more quickly and independent of the secondary
care, and, moreover, lower costs were subsequently incurred
in primary care.
The effect of education and counselling by the NP was not
reflected in the quality of life and severity outcomes. Possibly,
dermatologists achieved similar results in terms of the quality
of life because they prescribed ‘stronger’ medication, as mean
annual costs for medication were higher in the dermatologist
group.
Family costs in the NP group were half that in the derma-
tologist group, which was mainly explained by time costs and
out-of-pocket expenses. Lower time costs were determined by
the lower number of treatment visits per patient in children
aged < 4 years enabling parents to reduce the amount of lost
time for travelling to the hospital. Costs for out-of-pocket
expenses were higher in the dermatologist group indicating
that without education and counselling patients continued
searching for alternatives.
To our knowledge, this is the first clinical trial on cost-
effectiveness of treatment by the NP compared with treatment
by the dermatologist for eczema. We used IDQOL and CDLQI
scores as a primary outcome measure in the ICER, which is
unusual. However, decision-makers may view our results as
substantial cost-savings in the NP-treated group even if the
quality-of-life improvement after 12 months is on average
comparable. The cost-effectiveness analysis on satisfaction
clearly showed that treatment by the NP was cost-effective
based on lower costs and gained patient satisfaction in 92%
of the replicates, indicating that treatment by the NP may be
the preferred choice. However, there are limitations to this
preference. It should be considered that time investment by
the NP was almost twice that by the dermatologist which may
lead to lower productivity. The parents who participated in
this trial were predisposed to accept NPs, as a result of which
they may be more satisfied with NPs. It is also unclear
whether satisfaction is biased by the individual NP’s character-
istics, because in the current study treatment was mainly car-
ried out by one NP. Satisfaction is essential to understanding
Table 6 Methodological quality assessment
Study Cost analysis Cost perspective n
Quality assessment (CHEC) score
Yes No NA Yes (% of total)a
Su et al. 199718 Cost-of-illness Healthcare ⁄ family 48 7 6 6 54
Rathjen et al. 200021 Cost-of-illness Healthcare ⁄ family 204 5 8 6 38
Emerson et al. 200122 Cost-of-illness Healthcare ⁄ family 290 10 3 6 77
Weinmann et al. 200320 Cost-of-illness Healthcare 91 7 7 5 50
Ricci et al. 200623 Cost-of-illness Family 33 5 9 6 38
Witt et al. 200919 Cost-effectiveness Healthcare ⁄ family 87 14 5 0 74
CHEC, Consensus on Health Economic Criteria; NA, not applicable. aGeneric measure adjusted for NA.
 2011 The Authors
BJD  2011 British Association of Dermatologists 2011 165, pp600–611
608 Costs in children with eczema, M.L.A. Schuttelaar et al.
Table 7 Review cost assessment
Author Currency Cost components Cost units Mean annual costs per child (EURO, 2008)









Healthcare costs Visits (GP, dermatologist, paediatrician,
allergist)
158 295 1297
Hospital admission days 343 1154 486
Total healthcare costs 501 1448 2206
Family costs Visits (GP, SC contribution) 13 22 2692
Visits other (alternative practitioner) 70 57 23
Medication (+ dressings) 168 379 203
Other management strategiesa 178 363 463
Diet 0 61 111
Time costs 114 677 273





Moderate and severe eczema (n = 204)





Hospital admission days 384
Rehabilitation clinic 526
Total healthcare costs 1498
Family costs Contribution healthcare costs 326
Other management strategiesb 1095
Diet 326
Time costs (including loss of earnings) 2321
Total family costs 4068
Emerson et al.
200122
U.K. pound Eczema all severity (n = 290)c





Total healthcare costs all severity 90
Family costs Visits (private specialist) 3
Visits other (alternative therapist) 10
Other management strategiesa 14
Emollients, bath preparation, diet 10
Transport 8
Time costs 7
Total family costs 52
Weinmann et al.
200320
US dollar Eczema all severity (n = 90)


















Total healthcare costs 170 433 947
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patients’ preferences and providing feedback to professionals
and managers, but it may have limitations as a measure for
policy decisions. However, we showed that other indicators of
utility such as the quality-of-life outcomes and eczema severity
showed similar outcomes in both treatment groups. We col-
lected data on costs as accurately as possible and we showed
that treatment by the NP clearly generated lower costs. There-
fore, we suggest that similar quality-of-life and severity out-
comes, higher satisfaction with care and cost-savings are
sufficient criteria to prefer NPs in the treatment of children
with eczema.
Our overview of the costs showed that the costs associated
with eczema in children vary considerably between studies.
This can be explained partially by the differences in the study
populations regarding the severity of eczema. Studies based on
hospital-based recruitment generally include more severe
cases. Witt et al.19 reported annual healthcare costs of €331 in
children with mild eczema in secondary care. We noted
higher costs of €801 in children with moderate eczema in sec-
ondary care. Our results confirmed the findings by Su et al.18
and Ricci et al.23 that there is a positive association between
the costs and the severity of eczema. Another explanation for
the variation in healthcare costs between studies is that the
types of costs included were different. Some studies calculated
only eczema-specific costs while other studies also calculated
eczema-related costs, for example visits to a dietician or aller-
gologist. Rathjen et al.21 reported mean healthcare costs of
€1498; these consisted largely of sanatorium visits, which
exist only in the German healthcare system. Comparisons of
family costs were difficult because different types of family
costs were determined and the calculation of costs was differ-
ent in the various countries. The contribution of the family
for medication and emollients differed particularly between
countries. In the Netherlands, prescriptions for emollients and
protective dressings are paid by health insurance, but bath oil
has to be paid for by the family. This explains the lower fam-
ily costs in the Netherlands than in Italy where costs of emol-
lients are paid by the family.
In conclusion, international comparisons of the costs of
eczema in children are difficult because of the variation in the
types of costs determined, units and unit prices and eczema
severity between studies. To date, only a few international
studies have assessed the economic burden of eczema in chil-
dren and further studies are needed to calculate the disease
costs and also to investigate whether nurse-led care leads to
lower costs. Our economic evaluation showed that the costs of
Table 7 Continued
Author Currency Cost components Cost units Mean annual costs per child (EURO, 2008)
Ricci et al. 200623 US dollar Eczema all severity (n = 33)
Family costs Visits (SC + private specialist) 161
Medication 73
Emollients, detergents 808
Other management strategiesa 49










Visits (SC + private specialist) 34 172 222
Medication 84 59 84
Emollients, detergents 528 808 1013
Other management strategiesa 0 49 75
Diet 0 117 485
Total family costs 727 1228 1896
Witt et al. 200919 EURO Mean eczema severity mild (n = 52)
Healthcare costs Visits (dermatologist, paediatrician,
other physician)
157
Hospital admission days 0
Medication 174
Total healthcare costs 331
Family costs Medical aids and adjuvant therapies 211
Time costs 149
Total family costs 360
GP, general practitioner; SC, secondary care; HDM, house dust mite. aHDM avoidance intervention, nonirritating clothes. bHDM avoidance
intervention, disease-related holidays, home changing, other. cMild (n = 242), moderate (n = 41), severe (n = 7).
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care provided by the NPs were lower than care provided by
the dermatologists with comparable effectiveness. Therefore,
NP-led care is considered to be cost-effective. Because eczema
is a chronic disease, treatment by NPs may result in long-term
cost reductions both from a healthcare perspective and a fam-
ily point of view while maintaining effectiveness.
What’s already known about this topic?
• Care of eczema in children provided by nurse practitio-
ners (NPs) has similar outcomes in severity and the
quality of life, and higher satisfaction than that provided
by a dermatologist.
What does this study add?
• Substituting NPs for dermatologists in the treatment of
children with eczema results in lower healthcare costs
and family costs.
• The economic burden of treatment of eczema in chil-
dren is summarized in our review.
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